RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) |
1 Months Ended | |||
|---|---|---|---|---|
Mar. 26, 2026 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Jul. 28, 2016 |
|
| Director [Member] | ||||
| Compensation and interest payable | $ 1,361,519 | $ 1,271,685 | ||
| BioCorRx Inc. [Member] | ||||
| Common stock shares issued in exchange | 2,263,371 | |||
| Ownership interest | 12.15% | |||
| BioCorRx Pharmaceuticals [Member] | ||||
| Ownership retained percent | 75.80% | |||
| Management fee | 24.20% |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Percentage of assumed life insurance contract issued and outstanding to life insurance contract issued and outstanding after effect of reinsurance, as disclosed in supplementary reinsurance information. Includes, but is not limited to, dividend and adjustment to face value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|